Therapy-induced senescence (TIS), a lasting chemotherapy-evoked proliferative arrest of tumor cells, has been thought to be irreversible. As it turns out now, it makes tumour cells, which survive, more aggressive and worsens prognosis.
The European Commission has closed its very first infringement procedure under the Penalty Regulation. During an inspection at Roche’s UK headquarters in 2012 the British MHRA found data on 80,000 not properly reported adverse events of approved Roche meds, 15,161 of which included deaths.
https://european-biotechnology.com/wp-content/uploads/2024/04/Roche_c_.jpg5001280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-12-20 06:00:002017-12-20 06:00:00Roche does not have to pay US$685m fine
Hadean Ventures announced the launch of Hadean Capital I, a fund that will invest up to € 100 m in life science companies, with a particular focus on the Nordic region.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_2017_12_19_Hadean_Ventures_team.jpeg611915Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-12-18 18:25:352017-12-18 18:25:35A new fund from the north
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval at its December 2017 meeting, including two orphan medicines, and one biosimilar.
https://european-biotechnology.com/wp-content/uploads/2024/04/Zika.jpg21001500h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-12-17 10:08:002017-12-17 10:08:00Sally Ann Forsyth to join SBC
Belgian reMYND N.V. has out licenced worldwide commercialisation rights for its small molecule programme ReS39 in diabetes to Novo Nordisk A/S. The drug impedes death of insulin-producing beta cells by preventing the formation of cytotoxic islet amyloid polypeptide (IAPP) aggregates.
https://european-biotechnology.com/wp-content/uploads/2024/04/REMYNT_iNOVA4Health.jpg277389Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-12-15 09:27:552017-12-15 09:27:55reMYND in €350m diabetes deal with Novo
A new, non-invasive tuberculosis urine test prevents common disadvantages of the standard tuberculin skin test: Measuring lipoarabinomannan glycan from M. tuberculosis, it detects the active disease in early stage and does not interfere with co-infections or weakened immune system.
https://european-biotechnology.com/wp-content/uploads/2024/04/TB-scaled.jpg23632560Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-12-14 07:36:412017-12-14 07:36:41TB urine test outperforms standard of care
Life sciences investment group LSP has launched the largest fund in Europe dedicated to late-stage medical technology assets, including diagnostics and digital health.
Belgian start-up company Aelin Therapeutics NV secured the funds to push development of candidate drugs arising from its Pept-in protein knockdown platform, which harnesses protein aggregation to induce functional knockdown of target proteins.
https://european-biotechnology.com/wp-content/uploads/2024/04/Aelin.jpg467700Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-12-11 14:40:252017-12-11 14:40:25Aelin Therapeutics NV bags €27m in Series A financing
Cancer senescence: licence to kill
Latest NewsTherapy-induced senescence (TIS), a lasting chemotherapy-evoked proliferative arrest of tumor cells, has been thought to be irreversible. As it turns out now, it makes tumour cells, which survive, more aggressive and worsens prognosis.
Sheets of eye cells improve retina repair
Latest NewsScientists have generated sheets of human eye cells arranged on a biological scaffold, which they used to successfully treat vision disorders in rats.
Roche does not have to pay US$685m fine
Latest NewsThe European Commission has closed its very first infringement procedure under the Penalty Regulation. During an inspection at Roche’s UK headquarters in 2012 the British MHRA found data on 80,000 not properly reported adverse events of approved Roche meds, 15,161 of which included deaths.
A new fund from the north
Latest NewsHadean Ventures announced the launch of Hadean Capital I, a fund that will invest up to € 100 m in life science companies, with a particular focus on the Nordic region.
CHMP recommends EU approval of seven medicines
Latest NewsThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval at its December 2017 meeting, including two orphan medicines, and one biosimilar.
Sally Ann Forsyth to join SBC
AppointmentsStevenage Bioscience Catalyst (SBC) has announced that Dr. Sally Ann Forsyth is set to join the company as CEO in March 2018.
reMYND in €350m diabetes deal with Novo
Latest NewsBelgian reMYND N.V. has out licenced worldwide commercialisation rights for its small molecule programme ReS39 in diabetes to Novo Nordisk A/S. The drug impedes death of insulin-producing beta cells by preventing the formation of cytotoxic islet amyloid polypeptide (IAPP) aggregates.
TB urine test outperforms standard of care
Latest NewsA new, non-invasive tuberculosis urine test prevents common disadvantages of the standard tuberculin skin test: Measuring lipoarabinomannan glycan from M. tuberculosis, it detects the active disease in early stage and does not interfere with co-infections or weakened immune system.
LSP raises €280m for late-stage med-tech companies
Latest NewsLife sciences investment group LSP has launched the largest fund in Europe dedicated to late-stage medical technology assets, including diagnostics and digital health.
Aelin Therapeutics NV bags €27m in Series A financing
Latest NewsBelgian start-up company Aelin Therapeutics NV secured the funds to push development of candidate drugs arising from its Pept-in protein knockdown platform, which harnesses protein aggregation to induce functional knockdown of target proteins.